"XenoPort Reaches Licensing Deal With Reckitt Benckiser" published at 8:21 a.m. EDT incorrectly said XenoPort is planning a Phase IIB study of arbaclofen placarbil. Reckitt Benckiser is planning the study.

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Cencora (NYSE:COR)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Cencora Charts.
Cencora (NYSE:COR)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Cencora Charts.